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High levels of microsatellite instability (MSI-high) are a cardinal feature of colorectal tumors from patients with Lynch Syndrome.
Other key characteristics of Lynch Syndrome are that these patients experience fewer metastases and have enhanced survival when
compared to patients diagnosed with microsatellite stable (MSS) colorectal cancer. Many of the characteristics associated with
Lynch Syndrome including enhanced survival are also observed in patients with sporadic MSI-high colorectal cancer. In this
review we will present the current state of knowledge regarding the mechanisms that are utilized by the host to control colorectal
cancer in Lynch Syndrome and why these same mechanisms fail in MSS colorectal cancers.
1.Introduction
Although Warthin described a classic cancer prone family
(cancer family G) in the early 1900’s [1], relatively little
attention was given to “cancer families” until the 1960s when
Lynch described two large Midwestern cancer kindreds and
hypothesized that they were due to hereditary factors [2].
This hypothesis was widely dismissed and other theories
regarding the origins of cancer, such as exposure to an
environmental agent, were favored. Lynch also assessed the
cancer status of relatives of Warthin’s family G over six
generations, revealing an autosomal dominant pattern of
inheritance [3]. The hypothesis that cancer risk in such
families could be inherited was validated in the 1990s
when multiple groups identiﬁed regions of the genome
associated with colorectal cancer development [4–6]. The
recognition that some cancers were hereditary was signif-
icant, as it permitted increased surveillance and testing
of individuals who were at the greatest risk for disease
development. This also allowed patients to exercise some
level of control (i.e., seek early diagnosis) over disease
outcome.
Lynch Syndrome is a hereditary colorectal cancer (CRC)
syndrome. Patients with Lynch Syndrome experience early-
onset CRC as well as an increased risk of developing
certainextracoloniccancers[7–17]Insporadiccancers,there
are often point mutations in tumor suppressor genes and
protooncogenes including K-ras, p53 and APC [18–23].
These mutations are seldom observed in Lynch Syndrome
cancers [24–26]. The primary defect in Lynch Syndrome
cancers results in increased microsatellite instability due to
a mutation in the DNA mismatch repair genes; microsatellite
instability is not common in sporadic cancers [4–6, 27].
Lynch Syndrome tumors are more poorly diﬀerentiated
compared to other CRCs and are frequently characterized by
an excess of mucin, a Crohn’s-like reaction, and signet-cell
features [28]. These features would be expected to indicative
of a worse prognosis but represent a paradox in the case
of Lynch Syndrome patients. Despite these characteristics
associated with a poor prognosis, Lynch Syndrome patients
experienceenhancedsurvivalcomparedtopatientswithspo-
radic CRC [29]. The survival advantage of these patients is
of great interest to scientists and physicians alike and several
diﬀerent hypotheses have been considered in contributing to2 Clinical and Developmental Immunology
this.Factorsthatmayberesponsibleforimprovedsurvivalin
LynchSyndromepatientsincludeincreasedinﬁltrationofthe
tumor with T cells [30–33], reduced viability of tumor cells
due to genomic instability [34, 35], and the diploid nature of
Lynch Syndrome tumors [36, 37].
The concept that some tumors can be controlled by the
immune system is over 50 years old. It was observed that if
a tumor was resected from a mouse, reinjection of the same
tumor into the same mouse resulted in no tumor growth.
Injection of the tumor into a na¨ ıve mouse resulted in tumor
growth [38]. While these early experiments provided insight
into the role of the immune system in controlling cancer,
many tumors are weakly immunogenic as they are derived
from host tissue. Ergo, the host cannot mount a strong,
eﬀectiveimmuneresponsetothetumor.Theimmunesystem
can be exploited to control tumors that express foreign
antigens (such as the case with human papillomavirus
and cervical cancer vaccine). Lynch Syndrome tumors have
high levels of tumor inﬁltrating lymphocytes (TILs) [30–
33, 39–50], suggesting that tolerance does not exist to some
peptides expressed by these tumors. This paper will focus
on the potential role that the immune system may play in
enhancing prognosis in Lynch Syndrome, although other
cellular mechanisms may also inﬂuence host well-being.
Some of these mechanisms, such as the accumulation of
defects in genes associated with tumor viability [34, 35],
may work in conjunction with the immune mechanisms
described herein.
2. Overview of Lynch Syndrome
Lynch Syndrome, sometimes referred to as hereditary non-
polyposis colorectal cancer (HNPCC) comprises 2–5% of
all colorectal cancer cases [51–53] and develops due to an
autosomal dominant mutation in at least one of the DNA
mismatch repair genes [4–6, 51]. As these mutations are
highly penetrant, multiple generations of a family are fre-
quentlyaﬀectedbycancer[51,54].DefectiveDNAmismatch
repair results in the accumulation of insertions and dele-
tions within short repetitive sequences called microsatellites.
Alterations in the length of these microsatellites lead to a
condition known as microsatellite instability (MSI). Tumors
from individuals with defects in mismatch repair genes,
most common of which are mutL homolog 1 (MLH1) and
mutS homolog 2 (MSH2), have high levels of microsatellite
instability (MSI-high). It is important to note that while not
all cancer prone families with MSI-high CRCs are classiﬁed
as Lynch Syndrome, nevertheless, many of the features of
Lynch Syndrome are applicable to MSI-high CRC. MSI-high
sporadic CRCs are often caused by inactivation of mismatch
repair genes due to promoter hypermethylation of MLH1
[55–58].
The designations of Lynch Syndrome and HNPCC have
beenusedinterchangeablyformanyyears.However,theterm
HNPCC may also include cases of CRC that have features
associated with Lynch Syndrome but lack a mutation in
one of the mismatch repair genes [59]. These cases of CRC
are characterized as having Amsterdam criteria positivity
but lacking a mismatch repair germline mutation and are
referred to as familial CRC type X [60]. While in this paper
we have focused on Lynch Syndrome patients, we will use the
term HNPCC when that term was used in the papers being
discussed. Some studies have shown that patients with MSI-
high non-Lynch Syndrome CRC have a survival advantage
over patients microsatellite stable CRC [29], although this
remains controversial in that recent studies have failed to
conﬁrm this ﬁnding [61].
TheclinicalandpathologyfeaturesassociatedwithLynch
Syndrome are distinct from those of sporadic CRC [62,
63]. Tumors from Lynch Syndrome patients are typically
located proximal to the splenic ﬂexure [4, 64] and develop
at an earlier age (<50 years old) than colorectal tumors
from sporadic cases of cancer [62, 65]. Lynch Syndrome
tumors are also less likely to metastasize than non-Lynch
Syndrome tumors despite the presence of multiple colorectal
tumors [41, 64, 65]. Patients with Lynch Syndrome are
also predisposed to developing metachronous colorectal
cancers and extracolonic cancers including cancers of the
small bowel, ureter, renal pelvis, pancreas, biliary tract,
endometrium, ovaries, and brain at a higher than expected
rate [7, 9, 10, 12–15, 66, 67]. An increased risk of breast
and prostate cancer development is not usually associated
with Lynch Syndrome, although some studies have suggested
otherwise [16, 17, 68]. This topic has been extensively
reviewed recently [69].
Whileseveralgroupshavestudiedthecumulativelifetime
risk of Lynch Syndrome patients developing extracolonic
cancers [8, 66, 70–75], data may be skewed due to limited
sample sizes or overrepresentation of speciﬁc mutations in
the mismatch repair genes. A recent study examined the risk
of developing extracolonic cancers in 121 Lynch Syndrome
families in the United Kingdom [76]. Mutations in MLH1
were present in 51 families, while 59 families had mutations
in MSH2, and 11 families had mutations in MSH6 [76].
Eight hundred thirty nine mutation carriers were analyzed
and 282 extracolonic cancers identiﬁed [76]. Females had
a signiﬁcantly higher cumulative lifetime cancer incidence
compared with males, consistent with the association of
gynecological cancers (ovarian and endometrial) with Lynch
Syndrome. The risk of endometrial cancer development
in women with MSH6 mutations was approximately twice
the risk in women with MLH1 or MSH2 mutations [76].
Males had an increased risk of gastric cancer compared
to females in this study, although upon further analysis
of these data there was minimal risk for gastric cancer
development in individuals born after 1935. Individuals with
MSH2 mutations had a higher cumulative lifetime risk of
developing primary CNS tumors compared to nonmutation
carriers [76].
The name, hereditary nonpolyposis colorectal cancer,
may be somewhat misleading as adenomas that subsequently
develop into tumors are present in Lynch Syndrome patients
[77–80]. The presence of more than 10–15 adenomas is
extremely unusual in Lynch syndrome and may suggest
attenuated familial adenomatous polyposis [81, 82]. Anal-
ysis of adenomas from Lynch Syndrome patients demon-
strates that a high percentage of the adenomas (between
60 and 90%) are deﬁcient in mismatch repair proteins,Clinical and Developmental Immunology 3
indicating that the adenomas have similar phenotypes as
the colorectal cancers [79, 80, 83–88]. Data from clinical
surveys of colorectal cancer patients suggest that adenomas
from Lynch Syndrome patients may be more aggressive
than sporadic adenomas [89–94]. The mean time from
adenoma to carcinoma formation is 2-3 years in Lynch
Syndrome patients and 6–8 years in sporadic colorectal
cancer. The adenomas formed in Lynch Syndrome may
be more diﬃcult to detect due to the ﬂat morphology
that can be observed in some Lynch Syndrome patients
[95–98].
The Amsterdam criteria were developed in 1991 to assist
in the diagnosis of Lynch Syndrome [62]. Individuals who
meet the Amsterdam criteria have a better prognosis than
patients with microsatellite stable colorectal cancer [11, 41,
99, 100]. A study by Buckowitz et al. estimated the ﬁve-year
survival rate for MSH-high CRC that met the Amsterdam
criteriaat88%versus56%formicrosatellitestableCRC[41].
After adjusting for age and disease stage at time of diagnosis,
Watson et al. also demonstrated a survival advantage for
Lynch Syndrome CRC patients compared to patients with
sporadic CRC [11]. Of particular interest to both physicians
and basic scientists is why patients with Lynch Syndrome
enjoy this survival advantage over patients with sporadic
CRC. This ﬁnding, in combination with the increased rate
of primary extracolonic cancers [7, 9, 10, 12–15, 66, 67]
and decreased rates of metastases [41, 64, 65], suggests that
the Lynch Syndrome patients develop signiﬁcant defenses
to the cancer. A better understanding of what features of
Lynch Syndrome are key to the observed enhanced survival
would likely provide insights into not only the predominant
mechanisms employed by the host defense system to control
CRC, but also could permit the development of more
eﬀective therapies for both Lynch Syndrome and sporadic
CRC patients.
3. Increased lymphocyte Inﬁltration of Tumors
inLynchSyndrome Patients
The potential positive impact on disease outcome that dense
inﬁltrationoflymphocytesinvarioustumorshasbeenasub-
ject of considerable debate and speculation [30–33, 39–50].
A recent study of CRCs that did not take into consideration
the MSI status of the tumor found that patients with tumors
inﬁltrated with increased levels of cytotoxic and memory
(CD45RO+) T cells had improved outcome as compared
with patients with low levels of cytotoxic and memory T
cells [50]. This particular study focused on patients with
stage I and II CRC. Several studies have examined MSI-high
colorectal carcinomas and characterized both the number
and phenotype of the tumor inﬁltrating cells [30, 31, 41,
43, 47–49, 101, 102]. Studies by Smyrk et al. described an
increased level of tumor inﬁltrating lymphocytes (TILs) in
CRCs with high levels of microsatellite instability. In this
study, TIL’s in MSS, MSI-low and MSI-high CRCs were
correlated with microsatellite status, and it was determined
that tumors from HNPCC and other MSI-high CRCs had
increased lymphocyte inﬁltration compared to MSI-low or
M S St u m o r s[ 47]( Figure 1).
(a) (b)
Figure 1: Tumors from Lynch Syndrome patients experience in-
creased inﬁltration of tumors with CD3+ lymphocytes (b) com-
pared to non-Lynch Syndrome patients (a).
The prognostic signiﬁcance of the presence or absence of
TILs is a function of both the speciﬁc form of cancer, as well
as the nature of the inﬁltrate. In one study, nine of 11 MSI-
high patients with high levels of CD8+ intratumoral lym-
phocytes experienced tumor-free survival [48], suggesting a
correlation between CD8+ T cell inﬁltration of a tumor and
a positive disease outcome. The levels of activated cytotoxic
intraepithelial lymphocytes were signiﬁcantly increased in
MSI-high CRCs as compared to MSS CRCs [30, 31, 48].
Furthermore, lymphocytes from MSI-high CRC are more
likely to express high levels of CD8, a marker of cytotoxic
T cells, as well as granzyme B and perforin than non-MSI-
high tumors [30]. Together these data support a role for the
CD8+ T cells in the control of Lynch Syndrome tumors by
a cytotoxic mechanism aimed at killing tumor cells. Only
a small percentage of CD56+ cells (natural killer cells; NK
cells) was found, indicating that the majority of inﬁltrating
lymphocytes were likely CD8+ cytotoxic T cells [30]. These
data are consistent with immune activation of the adaptive
immune system.
CRCs that arise through mechanisms other than impair-
ment of the mismatch repair genes (for example, mutations
ink-rasorp53)alsohavesomeadditionalcharacteristicsthat
provide clues to the reduced survival times of individuals
with non-MSI-high cancers. In one study, tumors from
MSS and non-HNPCC MSI-high patients were examined
using quantitative RT-PCR. This particular study also com-
pared alterations between tumor and nontumor tissue. MSS
tumorshadenhancedlevelsofFoxp3,IL-6,IL-17,andTGF-β
transcripts as compared to MSI-high tumors [42]. Increased
levels of Foxp3, a marker of regulatory T cells (T regs), may
have signiﬁcant impact on the ability of the host to promote
as u ﬃcient immune response, as T regs downregulate
inﬂammation in an antigen-speciﬁc manner. The alterations
in cytokines would suggest that an environment conducive
to tumor growth and angiogenesis is present in the MSS
tumors [103, 104], creating a milieu that would favor the
development of metastases. In another study that did not
consider the microsatellite status of the tumor, increased
numbersofTregswereobservedinpatientswithCRC[105].
Interestingly, increased numbers of Tregs correlated with
morelimiteddiseaseversusmetastaticdisease.Giventhatthe
majority of CRCs are MSS, it is likely that these tumors are
overrepresented in this study [105] .Ar e c e n ts t u d yf r o mo u r4 Clinical and Developmental Immunology
group found no diﬀerences in the level of T reg inﬁltration
of MSS and MSI-high CRC using CD25 as a marker of T regs
[31].
The available data suggest that (1) Lynch Syndrome
patients have increased CD8+ cytotoxic T cells within the
tumor; (2) patients with sporadic MSS CRC have increased
levels of transcripts within the tumor that would promote
tumor growth and metastases. Adenomas from HNPCC
patients are also more likely to have adenoma inﬁltrating
lymphocytes (AILs) compared to adenomas from control
patients [92, 106], indicating that the processes responsible
for recruitment of the lymphocytes to the tumor are
established early in the development of the tumor. What
would account for the increased number of TILs in Lynch
Syndrome compared with sporadic CRC cases? Are these
TILs the key to enhanced survival? What are the speciﬁcities
of the T cell receptors expressed by the TILs? The answers
to these pertinent questions likely lie in the fundamental
defect in Lynch Syndrome patients’ DNA mismatch repair
genes. The role of the defective DNA mismatch repair genes
in generating targets for immune response is discussed
below.
4. How Could Defects inthe DNA Mismatch
Repair SystemProvidea SurvivalAdvantage
to HNPCC Patients?
4.1. Overview of the DNA Mismatch Repair System. Defects
in the DNA mismatch repair system increase the error rate
of replication by 100- to 1000-fold [107–109]. Areas of the
genome that contain repetitive sequences (microsatellites)
are particularly susceptible to insertions and deletions of
bases during the replication process [4, 110]. Strand slippage
of DNA polymerase and ineﬃcient proofreading contribute
to the vulnerability of microsatellites to errors during DNA
replication. The mismatch repair proteins are mediators
for ﬁxing these errors, thus allowing the host to maintain
genomic ﬁdelity [111–118]. To repair errors that occur
during DNA replication, the mechanism of repair must (a)
recognize the error; (b) remove the incorrect bases; (c)
resynthesize the DNA. Several excellent reviews are available
on the mismatch repair system [119–122]. In humans, the
error in the DNA sequence is recognized by a heterodimer
consisting of MSH2 and either MSH3 or MSH6. This
heterodimer binds the double stranded DNA at the site of
the error, which then permits binding of a second complex
consisting of MLH1 and either postmeiotic segregation
increased 2 (PMS2), PMS3, or MLH3 in an ATP-dependent
manner.Thebindingofthesecondheterodimerresultsinthe
movement of the complex along the DNA until it encounters
the PCNA:DNA polymerase and displaces it from the DNA.
Exonuclease I then excises nucleotides from the site of the
DNA polymerase to the site of the error on the daughter
strand thereby permitting resynthesis of the daughter strand.
The daughter strand is then resynthesized. Because MSH2
and MLH1 do not have alternative “stand in” proteins like
their binding partners, germline mutations in these genes
are most commonly associated with defects in the DNA
mismatch repair system and increased levels of microsatellite
instability in Lynch Syndrome. MSH6 and PMS2 mutations
are less common [111, 114, 123–127]. Regardless of which
mismatch repair gene is mutated, members of a given
Lynch Syndrome family normally have the same mutation,
although the ﬁrst occurrence of cancer may diﬀer in terms of
location and age of onset.
4.2. Consequences of Defects in DNA Mismatch Repair Genes.
During T cell development, immature T cells enter the
thymus and undergo positive and negative selection. As
a result of completing this process successfully, the host’s
T cell compartment contains a repertoire of cells that
are self-restricted and self-tolerant [128–130]. Under most
conditions the T cells will recognize peptides bound to the
host’s MHC molecules and will not have T cells reactive
to peptides that are derived from self proteins. Failure
to achieve the elimination of the self-reactive T cells can
result in autoimmune diseases such as type 1 diabetes and
rheumatoid arthritis. Because tumors are derived from host
tissue, the immune system often does not have T cells
in the repertoire that will react suﬃciently to the tumor.
Tumors that are immunogenic typically express mutated or
aberrantly expressed proteins. The mismatch repair system
is one mechanism to generate mutated proteins, and the key
to generating these proteins are mononucleotide repeats that
are found with in the genome.
Over 30 human genes containing mononucleotide
repeats of greater than 7 bases have been identiﬁed [122].
Common repetitive sequences in the human genome are
(A)n/(T)n and (CA)n/(GT)n [119, 131]. These genes are
more vulnerable to mutations than genes that do not contain
repetitive sequences. These repetitive sequences are found in
a number of coding regions of genes (coding microsatellites)
that are involved in apoptosis (APAP-1, BAX, BCL-10,
Caspase-5, FAS, RIZ) as well as mismatch repair genes
(MLH3, MSH3, MSH6). Growth factors and their receptors
(ACTRII, GRB-14, IGFIIR, TGFβRII, and WISP3) are also
aﬀected by the loss of mismatch repair functions [122, 132].
Because there are insertions and deletions in the repetitive
sequences within the coding region of these genes, tumors
from Lynch Syndrome patients often have alterations in the
translational reading frame of the aﬀected gene [132, 133].
This can result in the generation of altered proteins unique
to the tumor [134]. MSI-high tumors are unique in that a
frameshift mutation in the translational reading frame of the
gene can result in the generation of new peptides, some of
which may be immunogenic and recognized by the host’s
immune system as foreign. Because these frameshift peptides
(FSPs)areuniquetothetumorandnotpresentinotherareas
of the patient’s body, it is unlikely that central tolerance to
these FSPs has developed, and T cells with reactivity to these
peptides may exist in the host. Because of this, FSPs have the
potential to serve as a tumor-speciﬁc target for the immune
system in cancers (such as Lynch Syndrome) that have high
levels of MSI. T cells, particularly CD8+ T cells, could target
these FSPs, resulting in cytotoxic killing of tumor cells.
As early as 2001, the potential for FSPs to interact
with and stimulate T cell mediated immune responses
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in vitro, Linnebacher et al. demonstrated the ability of a
peptide generated from a frameshift of the TGFβIIR gene
to stimulate an in vitro immune response as measured by
IFNγ production and target cell lysis [134]. In a similar
study, Sæterdal et al. identiﬁed frameshift peptides derived
from TGFβRII and BAX were capable of stimulating T cell
mediatedimmuneresponses[136].Inthisstudy,twoofthree
MSI-high and three of three HNPCC patients had immune
responses to the TGFβRII-derived FSP. Together, these two
studies suggest that the requirements that are needed to
generate a sustained immune response to at least some FSPs
are present in some MSI-high patients. The ability to detect
responses in both the CD4+ and CD8+ T cell compartments
is signiﬁcant in that CD4+ T cells are normally required to
generate strong, sustainable CTL responses.
While FSPs have been determined to be immunogenic
[134, 136], a more recent study by Schwitalle et al. has
further explored the biological relevance of these FSPs in
vivo in HNPCC CRC patients and healthy HNPCC mutation
carriers [137]. TILs were isolated from tumor tissue of
MSI-H colorectal cancer tumors and assayed for cytotoxic
potential. TILs from HNPCC tumors were reactive to MSI-
high but not MSS tumor cells, indicating that TILs were
speciﬁc for peptides expressed by the MSI-high tumors.
TILs were examined for reactivity to FSPs as measured by
IFNγ release following exposure of the T cells to 24 FSPs
that were derived from 14 genes. Cytotoxic T cells were
identiﬁed that were reactive to FSPs including those derived
from TGFβRII, caspase 5, OCT, and AIM-2 [137]. The
implication of these studies is that individuals with MSI-
high tumors have (1) tumors that are immunogenic; and
( 2 )i m m u n ec e l l sc a p a b l eo ff o c u s i n gat a r g e t e da t t a c ko n
the tumor. Reactivity to FSPs was also detected in healthy
HNPCC carriers, suggesting that either (1) a protective
responseoccurredinindividualsthatdidnotdevelopcancer;
or (2) undetected adenoma development had occurred
in some patients, and the immune response was already
activated.
If the FSPs that are found in MSI-high are immunogenic,
then why cannot the immune system rid the body of the
tumor?Datademonstratethatimmuneevasionstrategiesare
likely invoked by the tumor. Because antigen presentation
to CD8+ T cells requires the formation of a peptide-MHC
Class I complex several groups have studied the expression of
class I on the surface of colorectal cancer tumors. There are
several mechanisms that could result in loss of MHC class I
expression on a cell’s surface. Most commonly, these defects
are related to the loss or mutation of β2 microglobulin, or
defects in the antigen processing components (for example,
LMP components), or defects in proteins involved in peptide
loading (TAP1/TAP2, tapasin) [138–142].
In considering that Lynch Syndrome patients have
increased levels of CD8+ T cells within the tumors, as well
as fewer metastases, it would be logical to hypothesize that
within the tumor environment there is a robust immune
response occurring. From the perspective of the tumor,
strong selective pressure would be expected to promote the
outgrowth of Class I negative cells, thereby permitting these
tumor cells to evade the MHC class I mediated immune
response. In examining MSS and MSI-high CRCs, distinct
mechanisms of class I loss were identiﬁed [139, 140, 143].
Several recent studies have focused on how the presence
of the CD8+ T cells could control antitumor responses
and what the potential targets of the CD8+ T cells are.
Focused answers to these questions require an explanation
as to why the proposed mechanism are eﬀective in Lynch
Syndrome patients, but not microsatellite stable colorectal
cancer patients.
Theconceptthatβ2microglobulinlossoccursincolorec-
tal cancer tumors with high levels of microsatellite instability
was examined by Bicknell et al. [139]. In this study, the
frequency of β2 microglobulin mutations was determined
in various cancers inclusive of colorectal, melanoma, breast,
ovary, and lymphoma. Mismatch repair mutations were
morelikelytobeassociatedwithβ2microglobulinmutations
than other defects in the antigen processing machinery
[139]. Furthermore, tumors that were not associated with
defective mismatch repair genes were not likely to have β2
microglobulin mutations.
In a study by Kloor et al., a high rate of total HLA class I
loss was observed in MSI-high tumors (∼60%) compared to
MSS tumors (∼30% loss) [94]. Further molecular analysis of
the tumors revealed mutations in β2 microglobulin (∼30%
of the tumors with Class I loss) and defects in TAP1 or
TAP2 (17% of the tumors with class I loss). The loss of
β2 microglobulin expression was likely due to frameshift
mutations resulting from the high level of microsatellite
instability [139]
A more recent study by Dierssen et al. [143] utilized
CRCs that were location matched (that is, both sporadic
MSI-high and LS tumors were right sided) [105]. In this
study, LS tumors were found to be signiﬁcantly associated
with a mutation in β2 microglobulin, while sporadic MSI-
high tumors were more likely to be the result of a mutation
in the antigen processing machinery such as the proteosome
(LMP2, LMP7, LMP10, and MBI), TAP1, TAP2, or chaper-
one proteins (calnexin, calreticulin, ERP57, and tapasin).
While both MSI-high right-sided tumors and HNPCC
hadincreasedlossofclassIexpressionontheirsurface,classI
expression was intact in MSS tumors. The basis of class I loss
was further investigated, and β2microglobulin mutations
were correlated with class I loss in HNPCC cases. In MSI-
high sporadic right sided tumor cases, multiple components
of the antigen processing machinery were found in all but
30% of the cases. TAP1/2, tapasin and LMP2 mutations were
the most common defects. MSS tumors appear to become
HLA negative via a third pathway—loss of heterozygosity
at chromosome 6p21.3, demonstrating that the evolution
of these three forms of colorectal cancer are unique in
the host [105]. Furthermore, these underlying diﬀerences
suggest that distinct treatment options are likely required.
Indeed, microsatellite instability may inﬂuence the response
to certain treatments, in particular 5-ﬂuorouracil (5-FU)
adjuvanttherapyinpatientswithMSI-highCRCs.Ribicetal.
[144] demonstrated that patients with MSI-high stage II or
stage III CRCs did not beneﬁt from adjuvant chemotherapy
compared to patients with stage II or stage III MSS or MSI-
low CRC.6 Clinical and Developmental Immunology
In examining the presence or absence of HLA class I
expression in MSI-high cancers in the context of the tumor
stage, and the presence or absence of distant metastases,
intuitively one may suggest that the loss of β2 microglobulin
and/or class I expression would be increased in tumors
that have metastasized. The rationale behind this hypothesis
wouldbethatintheabsenceofclassIexpressionTILscannot
appropriately perform their immunosurveillance function
and the tumor would metastasize from its primary site.
The association of β2 microglobulin mutations on CRC
progression was examined. In this study, tumors were strat-
iﬁed by stage [138]. Of the MSI-high adenomas examined,
almost16% werepositive formutations inβ2microglobulin,
indicating that these mutations are apparent prior to tumor
development. β2 microglobulin mutations accumulated as
tumors progressed from grades 1 (26.7% positive) through
grade 3 (43.5% positive). Of great interest however, was that
no stage 4 cancers in Lynch Syndrome had β2 microglobulin
mutations,suggestingthatβ2microglobulinmaybeinvolved
in the metastatic process [138]. This surprising ﬁnding
suggests mechanisms other than class I-mediated cytotoxic
processes are involved in tumor control.
If, after a period of time, increased loss of β2m i c r o g l o b -
ulin is found in colorectal cancers with high levels of
microsatellite instability, what mechanisms may be involved
in tumor control? Natural killer (NK) cell-mediated killing
has, as a requirement, downregulated levels of MHC class
I on the surface of the targeted cell. In this scenario, loss
of β2 microglobulin would result in loss of Class I, leading
to targeting of the tumor cell by NK cells. A small number
of studies have suggested that this mechanism of killing is
plausible in MSI-high colorectal cancers. Studies by Menon
et al. determined that tumors that were MLH-1 negative and
had decreased levels of HLA were more likely to contain
CD57+ cells [49]. Lack of class I expression has also been
associated with NK cell regulation and activation. Studies by
Dierssen et al. [143] have shown that CRCs from HNPCC
patients have decreased expression of HLA class I on their
surface [105].
A study examining the association between the number
of myeloperoxidase positive cells and microsatellite status
was performed by Roncucciet al. [145]. Myeloperoxidase is a
lysosomal enzyme highly expressed by neutrophils, and to a
lesser degree, by macrophages and monocytes. This marker
was used to assess the level of colonic inﬂammation, as it
is a key component of the neutrophil cytotoxic granules.
This study found a strong correlation between myeloperox-
idase staining and the presence of abnormal crypts, which
are presumed precursors of adenomas. Once tumors had
formed, increasing levels of myeloperoxidase staining was
observed in both MSS and MSI-high colorectal cancers.
However, MSI-high tumors had signiﬁcantly higher levels of
myeloperoxidase immunoreactivity as compared with MSS
tumors. The increase in myeloperoxidase staining in MSI-
high versus MSS tumors is consistent with an increased
inﬂammatory response in the MSI-high tumors [145]. This
study also suggests that mediators of the inﬂammatory
response (in particular neutrophil products) may drive
tumor development.
The balance between cell proliferation and cell death is
known to inﬂuence tumor progression and development. It
is key to consider not only the number of cells undergoing
apoptosis but also the ratio of cells experiencing apoptosis to
thenumberofcellsundergoingproliferationinthecontextof
tumorigenesis. Examination of these parameters is MSI-high
and MSS/MSI-low colorectal cancers found that MSI-high
tumors had signiﬁcantly decreased levels of proliferation
compared to MSI-low or MSS colorectal cancers [146].
When considering the role of the immune system in
tumor control, one must also consider the inherent char-
acteristics of the tumor, and what potential mechanisms
can be used by the tumor to evade immune surveillance in
vivo. Some studies have demonstrated that FasL expression
on tumor cells can interact with Fas-expressing TILs and
triggerapoptosisoftheFas-expressingTIL[32,45,147].This
situation has been termed “Fas counterattack.” When Fas
counterattack occurs, individuals with increased numbers
of TILs had a worse prognosis than individuals with low
numbers of TILs. In these studies, high levels of Fas L
expression by tumors results in apoptosis of the invading
TILs [32, 45, 147].
A recent study by Koornstra et al. examined FasL
expression and apoptosis in colorectal tumors from Lynch
Syndrome patients to assess whether Fas counterattack had a
roleinLynchSyndromepathologyorclinicalmanifestations,
in particular, the accelerated transformation from adenoma
to tumor [148]. Enumeration of the number of apoptotic
TILs and tumor cells in Lynch Syndrome and sporadic
colorectal cancer, as well as the number of FasL positive cells,
revealed no association between FasL expression, apoptosis,
and the number of TILs in Lynch Syndrome patients.
It is unclear as to whether the rate of apoptosis in the
adenomas is diﬀerent from the levels observed in the tumor.
A recent study demonstrated reduced levels of apoptosis
were observed in HNPCC adenomas [106]. The decrease
in apoptosis, which may in part be attributed to frameshift
mutations in apoptosis-related genes, may account for the
relatively fast transition from adenoma to tumor in HNPCC
patients.
5. Current Model of Tumor Control in
Lynch Syndrome
Based on the current state of knowledge, we propose the fol-
lowing model for the control of tumors in Lynch Syndrome
patients (Figure 2). CRCs in Lynch Syndrome patients have
a high degree of microsatellite instability. Mutations in the
DNA mismatch repair genes results in DNA strand slippage
and the generation of novel frameshift peptides within the
tumor.Becausethehosthasnotgeneratedimmunetolerance
to these peptides, these neopeptides are highly immunogenic
and the host generates a strong inﬂammatory response.
Immune cells are heavily recruited to the tumor site and the
inﬁltrateisdominatedbyCD8+Tcells.Becauseoftherobust
nature of the anti-tumor response, there is selective pressure
for the outgrowth of tumors that have mutations in β2
microglobulin,whichresultsinreducedantigenpresentation
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Figure 2: Defects in DNA mismatch repair genes leads to the generation of immunogenic Peptides expressed by the tumor. (a): The ﬁrst
sequenceisapartialsequenceoftheTGFβRIIgene.Notethetenbasestretchofadenines.Theareaofthegeneissusceptibletostrandslippage
during replication. When DNA mismatch repair genes are mutated, base-pairs can be lost or added during DNA replication. Additions or
deletions result in an altered reading frame. Using the TGFβRII gene as an example, the amino acid sequence is shown on the right. Bolded
animo acids are those amino acids represented by the nucleotide on the left. Unbolded sequences are those that are predicted based on the
mutation, using the nucleotide sequence of TGFβRII (120). (b): Following the generation of novel frameshift peptides to which the immune
system has not developed central tolerance to, the host can generate a robust immune response to the peptides that are uniquely expressed
by the tumor.
more frequent as tumor grade increases. Of interest however,
is the lack of these mutations in grade IV metastatic Lynch
Syndrome tumors. Tumors in Lynch Syndrome patients do
not appear to invoke other immune subversion processes
such as Fas counterattack of the inﬁltrating lymphocytes, as
evidenced by work correlating FasL expression with tumor
cell apoptosis and the number of TILs [148].
The hypothesis that the immune system of a host with a
mutation in a tumor suppressor gene (that is, one of the mis-
matchrepairgenes)coulddevelopastrategytoovercomethis
mutation (that is, developing a strong anti-tumor response)
is intriguing. The increased survival of Lynch Syndrome
patients also brings up some fascinating questions from an
evolutionary standpoint: (1) given that Lynch Syndrome
patients have a better prognosis than non-Lynch Syndrome
patients and the basis for the Syndrome is encoded in the
germ-lineispertinenttothequestionastowhethertherewill
there be increased rates of Lynch Syndrome (relative to non-
Lynch Syndrome CRCs) in generations to come? (2) does
the enhanced immune response, lack of metastatic events,
and enhanced survival lead to increased dissemination of
LynchSyndrome?Unfortunately,onecannoteasilyassessthis
question either retrospectively or prospectively. The history
of Lynch Syndrome is too short to accurately grasp the rates
of this form of CRC over time.
It is likely that Lynch Syndrome is underreported due
to the required testing. Unlike viruses or bacteria which
have extremely short generation times, the amount of time
it would take to observe such changes in disease incidence
in the human population would be beyond our lifetimes.
However, banking of genetic material could be helpful in
assessing the evolution of CRC in future generations. It is
also important to consider that the trend towards replacing
microsatellite instability screening with immunohistochem-
istry [149–152] ,al e s se x p e n s i v ea n dm o r ew i d e l ya v a i l a b l e
diagnostic tool, will also aﬀect our perceptions of the rates
of Lynch Syndrome, and thus also must be factored into any
estimates of changes in disease incidence over time.
6. FutureDirections
Despite the autosomal dominant inherited predisposition to
Lynch Syndrome, there is signiﬁcant variability in whether
an individual will develop cancer. With the relative com-
monplace nature of genome-wide association studies, sev-
eral single nucleotide polymorphisms have been identiﬁed8 Clinical and Developmental Immunology
which appear to inﬂuence colorectal cancer development.
Six variants associated with colorectal cancer development
have been identiﬁed on ﬁve chromosomes—8, 10, 11, 15,
and 18. Recently, Hans Vasen’s group in The Netherlands
performed a large (675 individuals in 127 families) study
that involved genotyping the six candidate loci (8q24.21,
8q23.3, 10p14, 11q23.1, 15q13.3, and 18q21.1) in Lynch Syn-
dromepatientsandanalyzedtheassociationbetweenspeciﬁc
variants and the risk of colorectal cancer development. Two
single nucleotide polymorphisms (SNPs) were identiﬁed—
rs6983266 on chromosome 8q24.21 and rs3802842 on
chromosome11q23.1—whichincreasetheriskofdeveloping
CRC in Lynch Syndrome individuals [153].
Microarray analysis of MSI-high and MSS cancers has
bolstered some of the immunohistochemical ﬁndings [154].
Granzyme A and granulysin were found to be upregulated
in MSI-H colorectal cancers as compared with MSS cancers,
indicating the immune mediators involved in cytotoxic lym-
phocyte functions are upregulated and the cells in the tumor
are likely to be activated. In addition to these mediators, this
study also found an increase in the expression of two heat
shock proteins—HSP-70 and HSP-110. Heat shock proteins
(also called stress proteins) are inducible molecules involved
inboththeinnateandadaptiveimmuneresponses,andoften
act as proinﬂammatory molecules [154].
Further clues into how the host controls tumor growth
and metastasis will likely be obtained from the types of
studies described above utilizing large-scale screening of
gene transcription, as well as high-density molecular array
to identify unique characteristics of the genomes of Lynch
Syndrome patients. Understanding these factors, regardless
of whether they are speciﬁc to certain Lynch Syndrome
mutations or whether they are reﬂective of all Lynch Syn-
drome patients, will provide insights into the mechanisms of
protection invoked in these individuals.
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